Analysts Offer Predictions for Quanterix FY2024 Earnings

Quanterix Co. (NASDAQ:QTRX) – Stock analysts at Leerink Partnrs decreased their FY2024 earnings estimates for shares of Quanterix in a research report issued to clients and investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings of ($0.94) per share for the year, down from their prior estimate of ($0.88). The consensus estimate for Quanterix’s current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix’s Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.18) EPS and FY2025 earnings at ($0.88) EPS.

Separately, TD Cowen raised their target price on Quanterix from $13.50 to $16.00 and gave the stock a “hold” rating in a research report on Wednesday, November 13th.

Quanterix Price Performance

QTRX stock opened at $9.42 on Thursday. Quanterix has a 1 year low of $9.16 and a 1 year high of $29.70. The company has a market cap of $362.90 million, a P/E ratio of -8.97 and a beta of 1.33. The stock’s fifty day moving average price is $11.99 and its 200-day moving average price is $12.68.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. nVerses Capital LLC bought a new stake in Quanterix during the third quarter valued at about $60,000. Peapack Gladstone Financial Corp purchased a new stake in shares of Quanterix during the third quarter worth about $131,000. SG Americas Securities LLC purchased a new stake in shares of Quanterix during the third quarter worth about $139,000. Canada Pension Plan Investment Board bought a new stake in Quanterix during the 2nd quarter valued at approximately $140,000. Finally, Hsbc Holdings PLC lifted its holdings in Quanterix by 34.7% in the 2nd quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock worth $164,000 after purchasing an additional 3,279 shares in the last quarter. 86.48% of the stock is owned by hedge funds and other institutional investors.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.